Phase 2 Lymphoma Trial, Recruiting NCT06925464 Sponsor: Beijing GoBroad Hospital Condition: Lymphoma
Back to Lymphoma

Phase 2 Lymphoma Trial, Recruiting

NCT06925464
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have a type of T-cell lymphoma that carries a specific marker called CD7, and whose cancer has come back or stopped responding to standard chemotherapy, with no other treatment options remaining (such as stem cell transplant or further chemotherapy)
  • People aged between 14 and 70 years old, either male or female
  • People whose general physical health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scoring system called the ECOG scale (scores 0–2) (confirm with trial site)
  • People who have a life expectancy of at least 60 days
  • People who are able to understand and sign a consent form before any screening begins; those aged 19–70 must be able to sign themselves, while those aged 14–18 must be aware of the consent form and have a legal guardian sign it separately

Who may not be able to join:

  • People whose cancer has spread significantly into the blood (more than 30% tumour load in the blood), regardless of whether they have previously had a stem cell transplant — or, for those who have had a donor stem cell transplant, cases where blood cells from that original donor are not available to prepare the treatment
  • People with raised pressure in the brain or reduced levels of consciousness
  • People with significant heart failure or serious irregular heart rhythms
  • People with severe breathing difficulties
  • People who have another type of cancer in addition to T-cell lymphoma
  • People with a serious blood clotting disorder called diffuse intravascular coagulation
  • People whose kidney function markers (creatinine and/or urea nitrogen) are 1.5 times or more above the normal range
  • People with sepsis or another infection that is not under control
  • People with diabetes that is not well controlled
  • People with severe mental health disorders
  • People who have significant abnormalities found on a brain MRI scan
  • People who have had an organ transplant (not including stem cell transplants)
  • Women of childbearing age who test positive for pregnancy (blood HCG test)
  • People who test positive for Hepatitis B, Hepatitis C, HIV/AIDS, or syphilis

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 86+ 18221015770

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Beijing GoBroad Hospital
Registry
ClinicalTrials.gov
Start date
1 April 2025
Est. completion
1 April 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Dose-limiting toxicity (DLT); Adverse events (AEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov